title: New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).
abstract: The treatment of GBM tumor recurrence is generally a hopeless challenge, since recurred tumor is resistant to the most common therapeutic efforts. Some partial results can be achieved by targeting local disease control, in view of the fact that 95% of recurrences occur locally. We present results concerning three pilot studies, all performed in recurrent GBM patients who underwent second surgery and have been treated systemically with temozolomide and locally through an Ommaya reservoire according to the following schedules: a) in 20 rGBM, 4 mg novantrone was delivered day 1,5 every 30 days; in 26 rGBM, 4 mg novantrone was delivered every 20 days in association with locoregional radioimmunotherapy (RIT); in 12 rGBM pegylated liposomal doxorubicin 4 mg was delivered day 1,5,10,15,20 with 20 days interval. Results seem very promising since there is an extension of disease free and survival, both of more than 50 % if results are evaluated in relation with the most frequent data of the literature.
authors.affiliation: Department of Neuroncology, Istituto Nazionale Neurologico C. Besta, Milano, Italy boiardi@istituto-besta.it
authors.forename: A
authors.initials: A
authors.lastname: Boiardi
authors.forename: M
authors.initials: M
authors.lastname: Eoli
authors.forename: A
authors.initials: A
authors.lastname: Salmaggi
authors.forename: E
authors.initials: E
authors.lastname: Lamperti
authors.forename: A
authors.initials: A
authors.lastname: Botturi
authors.forename: G
authors.initials: G
authors.lastname: Broggi
authors.forename: M
authors.initials: M
authors.lastname: Bartolomei
authors.forename: A
authors.initials: A
authors.lastname: Silvani
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001932:Brain Neoplasms / Q000401:mortality / Q000628:therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005909:Glioblastoma / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010865:Pilot Projects; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects; D016499:Radioimmunotherapy / Q000009:adverse effects; D000077204:Temozolomide
chemical_list: D000970:Antineoplastic Agents; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D003606:Dacarbazine; D004317:Doxorubicin; D008942:Mitoxantrone; D000077204:Temozolomide